Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

The role of bone marrow transplantation in acute promyelocytic leukemia

Bone Marrow Transplantation volume 28, pages 219–226 (2001)Cite this article

Abstract

Acute promyelocytic leukemia (APL) is characterized by a specific gene rearrangement and the generation of the PML-RARα fusion transcript which results from a translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy results in an apparent cure in 70–80% of patients. Both allogeneic (ALLO) and autologous (AUTO) hematopoietic stem cell transplantation (HSCT) are effective in acute myeloid leukemia (AML), but their role in APL is not clear given the excellent outcome with ATRA and chemotherapy. Several retrospective studies have analyzed the outcome of patients undergoing AUTO or ALLO-HSCT in first (CR1) or second (CR2) complete remission. Most of these studies have shown significant transplant-related mortality (TRM) with ALLO-HSCT, but a reduction in relapse rate compared with AUTO-HSCT. The high TRM with ALLO-HSCT and the excellent outcome with ATRA and chemotherapy do not justify recommending this procedure for the majority of patients in CR1. The role of AUTO-HSCT in CR1 also is unclear. A small subset of patients at high risk of relapse, possibly identifiable by a high white blood cell count at presentation may benefit from HSCT. Most patients with relapsed disease achieve CR2 with ATRA, arsenic trioxide, or combination therapy. However, it is not known if these responses are sustained or if consolidation with HSCT has a place in this setting. The outcome of AUTO-HSCT in CR2 using stem cells that are negative for PML-RARα is excellent. It is unclear whether ALLO-HSCT from an HLA-identical sibling is superior to AUTO-HSCT with PML-RARα-negative cells in CR2 since the former would be associated with graft-versus-leukemia effects and the latter with lower TRM. Alternatively, arsenic trioxide or re-treatment with ATRA, followed by intensive chemotherapy may also be effective. A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question. Bone Marrow Transplantation (2001) 28, 219–226.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Grimwade D . The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease Br J Haematol 1999 106: 591–613

    Article  CAS  Google Scholar 

  2. Larson RA, Kondo K, Vardiman JW et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia Am J Med 1984 76: 827–841

    Article  CAS  Google Scholar 

  3. Kakizuka A, Miller WH, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML Cell 1991 66: 663–674

    Article  CAS  Google Scholar 

  4. de The H, Lavau C, Marchio A et al. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR Cell 1991 66: 675–684

    Article  CAS  Google Scholar 

  5. Grignani F, Fagioli M, Alcalay M et al. Acute promyelocytic leukemia: from genetics to treatment Blood 1994 83: 10–25

    CAS  PubMed  Google Scholar 

  6. Breitman TR, Collins SJ, Keene BR . Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid Blood 1981 57: 1000–1004

    CAS  PubMed  Google Scholar 

  7. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia New Engl J Med 1997 337: 1021–1028

    Article  CAS  Google Scholar 

  8. Sanz MA, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia. PETHEMA group Blood 1999 94: 3015–3021

    CAS  PubMed  Google Scholar 

  9. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood 1999 94: 1192–1200

    CAS  PubMed  Google Scholar 

  10. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia Bone Marrow Transplant 1997 20: 821–826

    Article  CAS  Google Scholar 

  11. Gorin NC . Autologous stem cell transplantation in acute myelocytic leukemia Blood 1998 92: 1073–1090

    CAS  Google Scholar 

  12. Michallet M, Thomas X, Vernant JP et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM) Bone Marrow Transplant 2000 26: 1157–1163

    Article  CAS  Google Scholar 

  13. Chomienne C, Ballerini P, Balitrand N et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure–function relationship Blood 1990 76: 1710–1717

    CAS  PubMed  Google Scholar 

  14. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results Blood 1990 76: 1704–1709

    CAS  PubMed  Google Scholar 

  15. Elliott S, Taylor K, White S et al. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis Blood 1992 79: 1916–1919

    CAS  PubMed  Google Scholar 

  16. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood 1988 72: 567–572

    CAS  PubMed  Google Scholar 

  17. Warrell RP, Frankel SR, Miller WH et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid) New Engl J Med 1991 324: 1385–1393

    Article  Google Scholar 

  18. Ohno R, Yoshida H, Fukutani H et al. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare Leukemia 1993 7: 1722–1727

    CAS  PubMed  Google Scholar 

  19. Frankel SR, Eardley A, Heller G et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study Ann Intern Med 1994 120: 278–286

    Article  CAS  Google Scholar 

  20. Kanamaru A, Takemoto Y, Tanimoto M et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group Blood 1995 85: 1202–1206

    CAS  PubMed  Google Scholar 

  21. Fenaux P, Chevret S, Guerci A et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL 91 Group Leukemia 2000 8: 1371–1377

    Article  Google Scholar 

  22. Estey E, Thall PF, Pierce S et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine J Clin Oncol 1997 15: 483–490

    Article  CAS  Google Scholar 

  23. Castaigne S, Lefebvre P, Chomienne C et al. Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia Blood 1993 82: 3560–3563

    CAS  PubMed  Google Scholar 

  24. Chen G, Shen Z, Zhu AP . Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia Zhonghua Nei Ke Za Zhi 1997 36: 295–299

    CAS  PubMed  Google Scholar 

  25. Sanz M, Lo Coco F, Martin G et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups Blood 2000 96: 1247–1253

    CAS  PubMed  Google Scholar 

  26. Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study Cancer Chemother Pharmacol 1997 40: S25–S29

    Article  Google Scholar 

  27. Sun H, Ma L, Hu X . Treatment of acute promyelocytic leukemia by ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine Chin J Comb Trad Chin Med West Med 1992 12: 170–171

    Google Scholar 

  28. Zhang P, Wang S, Hu X . Arsenic trioxide treated 72 cases of acute promyelocytic leukemia Chin J Hematol 1996 17: 58–62

    Google Scholar 

  29. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 1997 89: 3354–3360

    CAS  PubMed  Google Scholar 

  30. Shao W, Fanelli M, Ferrara FF et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells J Natl Cancer Inst 1998 90: 124–133

    Article  CAS  Google Scholar 

  31. Zhu J, Koken MH, Quignon F et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia Proc Natl Acad Sci USA 1997 94: 3978–3983

    Article  CAS  Google Scholar 

  32. Chen GQ, Zhu J, Shi XG et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 1996 88: 1052–1061

    CAS  PubMed  Google Scholar 

  33. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide New Engl J Med 1998 339: 1341–1348

    Article  CAS  Google Scholar 

  34. Soignet S, Frankel S, Tallman M et al. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): the combined results and follow-up from the US pilot and multicenter trials Blood 2000 96: 827a (Abstr. 3575)

    Google Scholar 

  35. Thomas X, Anglaret B, Thiebaut A et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy Ann Hematol 1997 75: 195–200

    Article  CAS  Google Scholar 

  36. Cortes JE, Kantarjian H, O'Brien S et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia Cancer 1994 73: 2946–2952

    Article  CAS  Google Scholar 

  37. Thomas X, Dombret H, Cordonnier C et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia Leukemia 2000 14: 1006–1013

    Article  CAS  Google Scholar 

  38. Lo Coco F, Diverio D, Pandolfi PP et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia Lancet 1992 340: 1437–1438

    Article  CAS  Google Scholar 

  39. Slack JL, Gallagher RE . The molecular biology of acute promyelocytic leukemia Cancer Treat Res 1999 99: 75–124

    Article  CAS  Google Scholar 

  40. Diverio D, Riccioni R, Mandelli F, Lo Coco F . The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia Haematologica 1995 80: 155–160

    CAS  PubMed  Google Scholar 

  41. Fukutani H, Naoe T, Ohno R et al. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho) Leukemia 1995 9: 588–593

    CAS  PubMed  Google Scholar 

  42. Diverio D, Rossi V, Avvisati G et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-alpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. GIMEMA-AIEOP Multicenter ‘AIDA’ Trial Blood 1998 92: 784–789

    CAS  PubMed  Google Scholar 

  43. Roman J, Martin C, Torres A et al. Absence of detectable PML-RAR alpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia Bone Marrow Transplant 1997 19: 679–683

    Article  CAS  Google Scholar 

  44. Tobal K, Saunders MJ, Grey MR, Yin JA . Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia Br J Haematol 1995 90: 615–618

    Article  CAS  Google Scholar 

  45. Ikeda K, Sasaki K, Tasaka T et al. PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome Int J Hematol 1994 60: 197–205

    CAS  PubMed  Google Scholar 

  46. Grimwade D, Howe K, Langabeer S et al. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse Leukemia 1996 10: 61–66

    CAS  PubMed  Google Scholar 

  47. Lo Coco F, Diverio D, Avvisati G et al. Therapy of molecular relapse in acute promyelocytic leukemia Blood 1999 94: 2225–2229

    CAS  PubMed  Google Scholar 

  48. Lo Coco F, Diverio D, Falini B et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood 1999 94: 12–22

    PubMed  Google Scholar 

  49. Gorin NC, Najman A, Duhamel G . Autologous bone-marrow transplantation in acute myelocytic leukaemia Lancet 1977 1: 1050

    Article  CAS  Google Scholar 

  50. Sierra J, Brunet S, Granena A et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation J Clin Oncol 1996 14: 1353–1363

    Article  CAS  Google Scholar 

  51. Stein AS, O'Donnell MR, Chai A et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission J Clin Oncol 1996 14: 2206–2216

    Article  CAS  Google Scholar 

  52. Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission J Clin Oncol 1993 11: 314–319

    Article  CAS  Google Scholar 

  53. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups New Engl J Med 1995 332: 217–223

    Article  CAS  Google Scholar 

  54. Burnett AK, Goldstone AH, Stevens RM et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties Lancet 1998 351: 700–708

    Article  CAS  Google Scholar 

  55. Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 1997 90: 2978–2986

    CAS  Google Scholar 

  56. Löwenberg B, Verdonck LJ, Dekker AW et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study J Clin Oncol 1990 8: 287–294

    Article  Google Scholar 

  57. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission New Engl J Med 1998 339: 1649–1656

    Article  CAS  Google Scholar 

  58. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 2000 96: 4075–4083

    CAS  PubMed  Google Scholar 

  59. Mandelli F, Labopin M, Granena A et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT) Bone Marrow Transplant 1994 14: 293–298

    CAS  PubMed  Google Scholar 

  60. Meloni G, Diverio D, Vignetti M et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene Blood 1997 90: 1321–1325

    CAS  PubMed  Google Scholar 

  61. Sanz MA, de la Rubia J, Bonanad S et al. Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? Leukemia 1998 12: 992–995

    Article  CAS  Google Scholar 

  62. Ruiz-Arguelles GJ, Garces-Eisele J, Ruiz-Arguelles A . Continued complete remission after a PML/RAR-alpha+ autograft in acute promyelocytic leukaemia Eur J Haematol 1996 56: 186–187

    Article  CAS  Google Scholar 

  63. Sanz M, Arcese W, Rubia J de la et al. Stem cell transplantation (SCT) for acute promyelocytic leukemia in the ATRA era: A survey of the European Blood and Marrow Transplantation Group (EBMT) Blood 2000 96: (Suppl. 1) 522a (Abstr. 2247)

    Google Scholar 

  64. Takatsuki H, Umemura T, Sadamura S et al. Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation Leukemia 1995 9: 889–892

    CAS  PubMed  Google Scholar 

  65. Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Blood 1997 90: 2931–2938

    CAS  PubMed  Google Scholar 

  66. Galimberti S, Papineschi F, Carmignani A et al. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia Bone Marrow Transplant 1999 24: 345–348

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Melodee Nugent, MA, from the IBMTR Statistical Center for generating the outcome curves.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA

    C Nabhan, J Mehta & MS Tallman

Authors
  1. C Nabhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MS Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nabhan, C., Mehta, J. & Tallman, M. The role of bone marrow transplantation in acute promyelocytic leukemia. Bone Marrow Transplant 28, 219–226 (2001). https://doi.org/10.1038/sj.bmt.1703119

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703119

Keywords

This article is cited by

Search

Advanced search

Quick links